A population-based study on the effect of a routine second-look resection on survival in primary stage T1 bladder cancer.


Journal

Scandinavian journal of urology
ISSN: 2168-1813
Titre abrégé: Scand J Urol
Pays: Sweden
ID NLM: 101587186

Informations de publication

Date de publication:
Apr 2021
Historique:
pubmed: 9 3 2021
medline: 16 11 2021
entrez: 8 3 2021
Statut: ppublish

Résumé

To assess the value of second-look resection (SLR) in stage T1 bladder cancer (BCa) with respect to progression-free survival (PFS), and also the secondary outcomes recurrence-free survival (RFS), bladder-cancer-specific survival (CSS), and cystectomy-free survival (CFS). The study included 2456 patients diagnosed with stage T1 BCa 2004-2009 with 5-yr follow-up registration in the nationwide Bladder Cancer Data Base Sweden (BladderBaSe). PFS, RFS, CSS, and CFS were evaluated in stage T1 BCa patients with or without routine SLR, using univariate and multivariable Cox regression with adjustment for multiple confounders (age, gender, tumour grade, intravesical treatment, hospital volume, comorbidity, and educational level). SLR was performed in 642 (26%) individuals, and more frequently on patients who were aged < 75 yr, had grade 3 tumours, and had less comorbidity. There was no association between SLR and PFS (hazard ratio [HR] 1.1, confidence interval [CI] 0.85-1.3), RFS (HR 1.0, CI 0.90-1.2), CFS (HR 1.2, CI 0.95-1.5) or CSS (HR 1.1, CI 0.89-1.4). We found similar survival outcomes in patients with and patients without SLR, but our study is likely affected by selection mechanisms. A randomised study defining the role of SLR in stage T1 BCa would be highly relevant to guide current praxis.

Identifiants

pubmed: 33678124
doi: 10.1080/21681805.2021.1892179
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108-115

Auteurs

Johannes Bobjer (J)

Department of Urology, Skåne University Hospital, Malmö, Sweden.
Institution of Translational Medicine, Lund University, Malmö, Sweden.

Oskar Hagberg (O)

Institution of Translational Medicine, Lund University, Malmö, Sweden.

Firas Aljabery (F)

Department of Clinical and Experimental Medicine, Division of Urology, Linköping University, Linköping, Sweden.

Truls Gårdmark (T)

Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden.

Staffan Jahnson (S)

Department of Clinical and Experimental Medicine, Division of Urology, Linköping University, Linköping, Sweden.

Tomas Jerlström (T)

Department of Urology, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Amir Sherif (A)

Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.

Viveka Ströck (V)

Department of Urology, Sahlgrenska University Hospital and Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden.

Christel Häggström (C)

Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.

Lars Holmberg (L)

Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.

Fredrik Liedberg (F)

Department of Urology, Skåne University Hospital, Malmö, Sweden.
Institution of Translational Medicine, Lund University, Malmö, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH